Terms: = Liver cancer AND CD52, CDW52, EDDM5 AND Prognosis
2 results:
1. Novel miRNA-based drug CD5-2 reduces liver tumor growth in diethylnitrosamine-treated mice by normalizing tumor vasculature and altering immune infiltrate.
Liu K; Chen J; Zhao Y; Boland J; Ting KK; Lockwood G; McKenzie C; Kench J; Vadas MA; Gamble JR; McCaughan GW
Front Immunol; 2023; 14():1245708. PubMed ID: 37795103
[TBL] [Abstract] [Full Text] [Related]
2. Targeting Vascular Endothelial-Cadherin in Tumor-Associated Blood Vessels Promotes T-cell-Mediated Immunotherapy.
Zhao Y; Ting KK; Li J; Cogger VC; Chen J; Johansson-Percival A; Ngiow SF; Holst J; Grau G; Goel S; Muller T; Dejana E; McCaughan G; Smyth MJ; Ganss R; Vadas MA; Gamble JR
Cancer Res; 2017 Aug; 77(16):4434-4447. PubMed ID: 28655790
[TBL] [Abstract] [Full Text] [Related]
